Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3133 | Psycho-Social Questionnaire Wiki | 0.71 |
| drug4197 | Valsartan (Diovan) Wiki | 0.71 |
| drug4419 | cenicriviroc Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.06 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.06 |
| D055371 | Acute Lung Injury NIH | 0.06 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
We hypothesize that early institution of TNFα inhibitor therapy in patients with severe COVID-19 infections will prevent further clinical deterioration and reduce the need for advanced cardiorespiratory support and early mortality. To address this hypothesis, a prospective, single center, phase 2 trial is proposed to assess the efficacy of infliximab or infliximab-abda in hospitalized adult patients with severe or critical COVID-19. Observations from this study will inform the conduct of prospective randomized controlled studies to follow.
Description: Time to improvement in oxygenation
Measure: Time to improvement in oxygenation Time: 28 DaysDescription: 28-day mortality
Measure: 28-day mortality Time: 28 DaysDescription: Assessment of cytokine and inflammatory profile at baseline and at 48 hours after therapy
Measure: Assessment of cytokine and inflammatory profile at baseline and at 48 hours after therapy Time: 28 DaysDescription: Qualitative and quantitative toxicity
Measure: Qualitative and quantitative toxicity Time: 28 DaysDescription: incidence and duration of supplemental oxygen administration by nasal cannula, simple face mask, or other similar oxygen delivery device
Measure: incidence and duration of supplemental oxygen administration Time: 28 DaysDescription: Incidence and duration of non-invasive ventilation or by non-rebreather mask or high-flow nasal cannula
Measure: Incidence and duration of non-invasive ventilation or by non-rebreather mask or high-flow nasal cannula Time: 28 DaysDescription: Incidence and duration of mechanical ventilation
Measure: Incidence and duration of mechanical ventilation Time: 28 DaysDescription: Incidence and duration of vasopressor support
Measure: Incidence and duration of vasopressor support Time: 28 DaysDescription: Incidence and duration of extracorporeal membrane oxygenation
Measure: Incidence and duration of extracorporeal membrane oxygenation Time: 28 DaysDescription: Duration of fever
Measure: Duration of fever Time: 28 DaysDescription: Correlation of cytokine profile to clinical outcomes specified in primary and secondary objectives
Measure: Correlation of cytokine profile to clinical outcomes specified in primary and secondary objectives Time: 28 DaysDescription: Duration of hospitalization
Measure: Duration of hospitalization Time: 28 DaysDescription: Secondary infections
Measure: Secondary infections Time: 28 DaysACTIV-1 IM is a master protocol designed to evaluate multiple investigational agents for the treatment of moderately or severely ill patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The research objectives are to evaluate each agent with respect to speed of recovery, mortality, illness severity, and hospital resource utilization. Each agent will be evaluated as add-on therapy to the standard of care (SoC) in use at the local clinics, including remdesivir (provided). The SoC may change during the course of the study based on other research findings. Comparisons of the agents among themselves is not a research objective. The study population corresponds to moderately and severely ill patients infected with the coronavirus disease 2019 (COVID-19) virus. Recruitment will target patients already hospitalized for treatment of COVID-19 infection as well as patients being treated for COVID-19 infection in Emergency Departments while waiting to be admitted to the hospital. Patients both in and out of the ICU are included in the study population.
Description: time to recovery by Day 29
Measure: Number of patients that recovered from COVID-19 Time: days 1-29Description: Number of patients hospitalized on invasive mechanical ventilation
Measure: Change in number of patients hospitalized on invasive mechanical ventilation Time: Days 15 and 29Description: 8-point ordinal clinical scale assessed
Measure: number of patients that improved clinically Time: Days 3, 5, 8, 11, 15, 29, and 60Description: mortality rate
Measure: Number of patient deaths Time: Day 14Description: compared to baseline the amount of supplementation oxygen
Measure: Number of patients with decreased supplemental oxygenation needed Time: Day 29Description: assessment of non-invasive ventilation/ high flow oxygen up to day 29
Measure: Change in number of patients needing non-invasive ventilation/ high flow oxygen Time: Day 29Description: number of days in the hospital
Measure: Number of days patients are in the hospital Time: Days 3, 5, 8, 11, 15, 22, and 29Description: Cumulative incidence of SAEs and AEs of grade 3 and 4
Measure: Number of SAEs and AEs of grade 3 and 4 Time: Days 3, 5, 8, 11, 15, 22, and 29Description: Number of patients with changes in abnormal WBC counts
Measure: Number of patients with changes in abnormal WBC counts Time: Days 3, 5, 8, 11, 15, and 29Description: time to discharge or to a NEWS of <=2 and maintained for 24 hours
Measure: Number of patients with National Early Warning Scores (NEWS) <=2 Time: Days 3, 5, 8, 11, 15, and 29Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports